RMP-7: Began a third Phase II trial in up to 90 patients, measuring time to tumor progression and deterioration in clinical status, compared to treatment with c

Alkermes Inc. (ALKS), Cambridge, Mass. Product: RMP-7, which binds to receptors on the blood-brain barrier to trigger brief opening of the barrier, to deliver carboplatin Indication: Recurrent glioma ...